Central nervous system infections -: a potential complication of systemic immunotherapy

被引:22
作者
Hemmer, B
Frohman, E
Hartung, HP
Stüve, O
机构
[1] Univ Dusseldorf, Dept Neurol, Neuroimmunol Grp, D-40225 Dusseldorf, Germany
[2] Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75235 USA
[3] VA N Texas Hlth Care Syst, Med Serv, Neurol Sect, Dallas, TX USA
关键词
central nervous system immune surveillance; immunosuppression; immunotherapy; multiple sclerosis; natalizumab; Tysabri;
D O I
10.1097/01.wco.0000227037.70329.b0
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose of review Multiple sclerosis is a chronic inflammatory disease of the central nervous system, characterized by demyelination and axonal damage. With the emergence of more efficient immune therapies, severe sometimes even fatal central nervous system infections were observed. This review will address the role of the systemic immune system in central nervous system immune surveillance and discuss implications for the development of novel immunotherapies in multiple sclerosis. tRecent findings In the last decade, a number of immunosuppressive and immunomodulatory agents have been approved for the treatment of multiple sclerosis, based on the results of double-blind placebo-controlled randomized clinical trials. A better understanding of the pathogenesis of the disease has prompted exploration of the therapeutic utility of new drugs that more potently disrupt the pathophysiological cascade of events that culminates in central nervous system tissue damage. One potential side-effect of these newer therapies is their interference with the control of central nervous system infections by the immune system. Summary Any increase in potency of multiple sclerosis therapies could well interfere with protective immunosurveillance of the central nervous system. One possible outcome is an increased incidence of opportunistic infections. A heightened vigilance for central nervous system infections in the setting of immunosuppression is necessary to prevent serious side-effects in the future.
引用
收藏
页码:271 / 276
页数:6
相关论文
共 59 条
[1]   Natalizumab and progressive multifocal leukoencephalopathy [J].
Adelman, B ;
Sandrock, A ;
Panzara, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (04) :432-433
[2]   Determinants of human B cell migration across brain endothelial cells [J].
Alter, A ;
Duddy, M ;
Hebert, S ;
Biernacki, K ;
Prat, A ;
Antel, JP ;
Yong, VW ;
Nuttall, RK ;
Pennington, CJ ;
Edwards, DR ;
Bar-Or, A .
JOURNAL OF IMMUNOLOGY, 2003, 170 (09) :4497-4505
[3]   Clonal expansions of CD8+ T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction [J].
Babbe, H ;
Roers, A ;
Waisman, A ;
Lassmann, H ;
Goebels, N ;
Hohlfeld, R ;
Friese, M ;
Schröder, R ;
Deckert, M ;
Schmidt, S ;
Ravid, R ;
Rajewsky, K .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (03) :393-404
[4]  
Barata C H, 2000, Rev Soc Bras Med Trop, V33, P609, DOI 10.1590/S0037-86822000000600015
[5]   Progressive multifocal leukoencephalopathy [J].
Berger, JR ;
Major, EO .
SEMINARS IN NEUROLOGY, 1999, 19 (02) :193-200
[6]   Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β [J].
Bielekova, B ;
Richert, N ;
Howard, T ;
Blevins, G ;
Markovic-Plese, S ;
McCartin, J ;
Würfel, J ;
Ohayon, J ;
Waidmann, TA ;
McFarland, HF ;
Martin, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (23) :8705-8708
[7]   Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy [J].
Bossolasco, S ;
Calori, G ;
Moretti, F ;
Boschini, A ;
Bertelli, D ;
Mena, M ;
Gerevini, S ;
Bestetti, A ;
Pedale, R ;
Sala, S ;
Sala, S ;
Lazzarin, A ;
Cinque, P .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (05) :738-744
[8]   Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis [J].
Cepok, S ;
Rosche, B ;
Grummel, V ;
Vogel, F ;
Zhou, D ;
Sayn, J ;
Sommer, N ;
Hartung, HP ;
Hemmer, B .
BRAIN, 2005, 128 :1667-1676
[9]   PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY FOLLOWING TREATMENT FOR WEGENERS GRANULOMATOSIS [J].
CHOY, DSJ ;
WEISS, A ;
LIN, PT .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (05) :600-601
[10]  
Coles AJ, 1999, ANN NEUROL, V46, P296, DOI 10.1002/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO